Genzyme and vaccines push up Sanofi's first-quarter results
Reuters
Published Apr 26, 2019 06:58
Genzyme and vaccines push up Sanofi's first-quarter results
PARIS (Reuters) - Sanofi (PA:SASY) upheld a long-awaited return to growth on Friday with higher profits and revenues for the first quarter, once again led by a stellar 31 percent sales increase at its rare diseases Genzyme unit.
The French drugmaker, which also posted a strong sales increase at its vaccines division confirmed its full-year outlook.
Net income rose 9 percent to 1.77 billion euros (£1.5 billion) at constant exchange rates in the first quarter on sales of 8.4 billion. Analysts polled by Reuters with Infront Data had forecast average net income of 1.67 billion euros and sales of 8.36 billion.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.